CellSeed

CellSeed Cash Flow per Share

The Operating Cash Flow per Share of CellSeed (7776.T) as of Oct 30, 2026 is -28.43 JPY. In the previous year, Operating Cash Flow per Share was -24.98 JPY — a change of 13.79% (lower).

Cash Flow per Share

-28.43JPY

YoY

13.79%

Last updated:

Operating Cash Flow per Share of CellSeed is 2025 -28.43 JPY. Operating Cash Flow per Share of CellSeed was 2024 -24.98 JPY. It decreases by 13.79% lower compared to the previous year.

The CellSeed Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
-26.78 JPY
Jan 1, 2019
-0.04 JPY
Jan 1, 2020
-43.77 JPY
Jan 1, 2021
-46.01 JPY
Jan 1, 2022
-31.27 JPY
Jan 1, 2023
-24.90 JPY
Jan 1, 2024
-24.98 JPY
Jan 1, 2025
-28.43 JPY
The CellSeed Cash Flow per Share history
YEARCash Flow per ShareYoY
-28.43JPY+13.79%
-24.98JPY+0.35%
-24.90JPY-20.38%
-31.27JPY-32.04%
-46.01JPY+5.12%
-43.77JPY+98,376.45%
-0.04JPY-99.83%
-26.78JPY-59.03%
-65.36JPY+198.96%
-21.86JPY+26.22%
-17.32JPY+10.84%
-15.63JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

Operating Cash Flow per Share of CellSeed is -28.43 JPY in 2025.

Operating Cash Flow per Share of CellSeed changed from -24.98 JPY to -28.43 JPY, representing a 13.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share CellSeed since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CellSeed

All Key Metrics — CellSeed